Advertisement

Medical Oncology

, 36:27 | Cite as

Metastatic castration resistant prostate cancer with squamous cell, small cell, and sarcomatoid elements—a clinicopathologic and genomic sequencing-based discussion

  • Steven C. Weindorf
  • Alexander S. Taylor
  • Chandan Kumar-Sinha
  • Dan Robinson
  • Yi-Mi Wu
  • Xuhong Cao
  • Daniel E. Spratt
  • Michelle M. Kim
  • Amir Lagstein
  • Arul M. Chinnaiyan
  • Rohit MehraEmail author
Short Communication

Abstract

Histologic variants are uncommon but well reported amongst cases of prostatic adenocarcinoma, including those in the setting of hormonal and/or chemoradiation therapy and castration resistance. However, the spectrum of morphologic phenotypes and molecular alterations present in such histologic variants are still incompletely understood. Herein, we describe a case of metastatic prostatic adenocarcinoma with hormonal and chemoradiation therapy-associated differentiation, displaying a combination of squamous cell, small cell, and sarcomatoid elements. The morphologic, immunohistochemical, and molecular observations are discussed with attention given to the gene alterations present, including in TP53, NF1, AR, PTEN, and RB1. Finally, we will compare our findings with those observed in uncommonly reported similar cases so as to detail the molecular underpinnings of such processes which may carry therapeutic implications.

Keywords

Prostate cancer Small cell Squamous Sarcomatoid Castration resistant Sequencing 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Fine SW. Variants and unusual patterns of prostate cancer: clinicopathologic and differential diagnostic considerations. Adv Anat Pathol. 2012;19(4):204–16.  https://doi.org/10.1097/PAP.0b013e31825c6b92.CrossRefPubMedGoogle Scholar
  2. 2.
    Nabi G, Ansari MS, Singh I, Sharma MC, Dogra PN. Primary squamous cell carcinoma of the prostate: a rare clinicopathological entity: report of 2 cases and review of literature. Urol Int. 2001;66(4):216–9.  https://doi.org/10.1159/000056618.CrossRefPubMedGoogle Scholar
  3. 3.
    Hansel DE, Epstein JI. Sarcomatoid carcinoma of the prostate: a study of 42 cases. Am J Surg Pathol. 2006;30(10):1316–21.  https://doi.org/10.1097/01.pas.0000209838.92842.bf.CrossRefPubMedGoogle Scholar
  4. 4.
    Perez N, Castillo M, Santos Y, Truan D, Gutierrez R, Franco A, et al. Carcinosarcoma of the prostate: two cases with distinctive morphologic and immunohistochemical findings. Virchows Arch. 2005;446(5):511–6.  https://doi.org/10.1007/s00428-005-1239-x.CrossRefPubMedGoogle Scholar
  5. 5.
    Rogers CG, Parwani A, Tekes A, Schoenberg MP, Epstein JI. Carcinosarcoma of the prostate with urothelial and squamous components. J Urol. 2005;173(2):439–40.  https://doi.org/10.1097/01.ju.0000149969.76999.7c.CrossRefPubMedGoogle Scholar
  6. 6.
    Robinson DR, Wu YM, Lonigro RJ, Vats P, Cobain E, Everett J, et al. Integrative clinical genomics of metastatic cancer. Nature. 2017;548(7667):297–303.  https://doi.org/10.1038/nature23306.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Little NA, Wiener JS, Walther PJ, Paulson DF, Anderson EE. Squamous cell carcinoma of the prostate: 2 cases of a rare malignancy and review of the literature. J Urol. 1993;149(1):137–9.CrossRefGoogle Scholar
  8. 8.
    Cerasuolo M, Paris D, Iannotti FA, Melck D, Verde R, Mazzarella E, et al. Neuroendocrine transdifferentiation in human prostate cancer cells: an integrated approach. Cancer Res. 2015;75(15):2975–86.  https://doi.org/10.1158/0008-5472.CAN-14-3830.CrossRefPubMedGoogle Scholar
  9. 9.
    Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science. 2017;355(6320):84–8.  https://doi.org/10.1126/science.aah4307.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Ordonez NG, Ayala AG, von Eschenbach AC, Mackay B, Hanssen G. Immunoperoxidase localization of prostatic acid phosphatase in prostatic carcinoma with sarcomatoid changes. Urology. 1982;19(2):210–4.CrossRefGoogle Scholar
  11. 11.
    Philpott C, Tovell H, Frayling IM, Cooper DN, Upadhyaya M. The NF1 somatic mutational landscape in sporadic human cancers. Hum Genom. 2017;11(1):13.  https://doi.org/10.1186/s40246-017-0109-3.CrossRefGoogle Scholar
  12. 12.
    cBioPortal for Cancer Genomics [database on the Internet]. Accessed: October 2018.Google Scholar
  13. 13.
    Kelly K, Balk SP. Reprogramming to resist. Science. 2017;355(6320):29–30.  https://doi.org/10.1126/science.aam5355.CrossRefPubMedGoogle Scholar
  14. 14.
    Millis SZ, Stephens PJ, Ross JS, Miller VA, Ali SM, Wang J. Comprehensive genomic sequencing of prostate sarcomatoid carcinoma tumors identifies differences in genomic alterations compared to prostate adenocarcinoma tumors. J Clin Oncol. 2017;35(6_suppl):226.  https://doi.org/10.1200/JCO.2017.35.6_suppl.226.CrossRefGoogle Scholar
  15. 15.
    Vlachostergios PJ, Puca L, Beltran H. Emerging variants of castration-resistant prostate cancer. Curr Oncol Rep. 2017;19(5):32.  https://doi.org/10.1007/s11912-017-0593-6.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Steven C. Weindorf
    • 1
  • Alexander S. Taylor
    • 1
  • Chandan Kumar-Sinha
    • 1
    • 5
  • Dan Robinson
    • 1
    • 5
  • Yi-Mi Wu
    • 1
    • 5
  • Xuhong Cao
    • 5
  • Daniel E. Spratt
    • 3
    • 4
  • Michelle M. Kim
    • 3
  • Amir Lagstein
    • 1
  • Arul M. Chinnaiyan
    • 1
    • 2
    • 4
    • 5
    • 6
  • Rohit Mehra
    • 1
    • 4
    • 5
    Email author
  1. 1.Department of PathologyUniversity of Michigan Medical SchoolAnn ArborUSA
  2. 2.Department of UrologyUniversity of Michigan Medical SchoolAnn ArborUSA
  3. 3.Department of Radiation OncologyUniversity of Michigan Medical SchoolAnn ArborUSA
  4. 4.Rogel Cancer CenterMichigan MedicineAnn ArborUSA
  5. 5.Michigan Center for Translational PathologyAnn ArborUSA
  6. 6.Howard Hughes Medical InstituteAnn ArborUSA

Personalised recommendations